Should You Buy the Dip in JPMorgan Following its Drop After Q1 Earnings?

NYSE: JPM | JPMorgan Chase & Co. News, Ratings, and Charts

JPM – Shares of leading investment management company JPMorgan Chase (JPM) dipped nearly 6% in price after the company reported its fourth-quarter earnings. In addition, the company lowered its guidance for 2022 over concerns related to inflationary pressure and a tight labor market. So, would it be worth adding the stock to one’s portfolio? Let’s find out.

 With $3.1 trillion in assets under management, JPMorgan Chase & Co. (JPM) is a leading global financial services firm with operations worldwide. The company’s shares have gained 9.1% in price over the past year, driven by solid topline growth across all segments.

However, the stock declined 6.2% after the JPM posted unimpressive quarterly results last week. Closing yesterday’s trading session at $151.27, the stock is currently trading 12.5% below its 52-week high of 172.96, which it hit on Oct. 25, 2021. In addition, last month, the bank had to pay a $200 million fine to resolve claims that its Wall Street business allowed employees to avoid record-keeping regulations by using texting applications.

Also, JPM CFO Jeremy Barnum lowered his companywide guidance citing inflationary pressures and a tight labor market. JPM expects its expenses to rise 8% to almost $77 billion in 2022, causing the company’s returns to dip compared to recent years.

Here’s what could shape JPM’s performance in the near term:

Mixed Financials

During the fourth quarter, ended December 31, 2021, JPM’s net revenue increased 1% year-over-year to $30.3 billion. Its net interest income grew 3% from its year-ago value to $13.7 billion. However, its net income declined 14% from the prior-year quarter to $10.4 billion, while its EPS decreased 12.1% year-over-year to $3.33. In addition, its noninterest expense grew 11% year-over-year to $17.9 billion.

Consensus Rating and Price Target Indicate Potential Upside

Of 18 Wall Street analysts who rated JPM, 10 rated it Buy, and seven rated it Hold. The 12-month median price target of $178.39 indicates a 17.9% potential upside. The price targets range from a low of $141.00 to a high of $200.00.

POWR Ratings Reflect Uncertainty

JPM has an overall C rating, which equates to Neutral in our proprietary POWR Ratings system. The POWR ratings are calculated considering 118 different factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight different categories. JPM has a C grade for Sentiment and Quality. JPM’s mixed financials and consensus estimates are consistent with these grades.

Of the 10 stocks in the D-rated Money Center Banks industry, JPM is ranked #5.

Beyond what I’ve stated above, one can view JPM ratings for Growth, Value, Momentum, and Stability here.

Bottom Line

JPM is a global leader in investment management and has exhibited solid operational performance over the past years. However, the company delivered an unimpressive quarterly earnings release last week. In addition, analysts expect its EPS to decline 24.1% in the next quarter. Moreover, JPM has lowered its 2022 guidance, citing inflationary pressures that are making its near-term prospects uncertain. So, we believe it’s better to wait before scooping up its shares.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


JPM shares were trading at $149.94 per share on Wednesday morning, down $1.33 (-0.88%). Year-to-date, JPM has declined -4.74%, versus a -4.01% rise in the benchmark S&P 500 index during the same period.


About the Author: Pragya Pandey


Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
JPMGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Expert Predicts 3-6 Months of Pain

2 important market developments are leading market expert Steve Reitmeister to predict 3 to 6 months of painful market conditions pushing the S&P 500 (SPY) lower. Read on for the full story...

3 Pharmaceutical Stocks Addressing Global Health Challenges

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more...

3 Tech Stocks Analysts Say Are "Strong Buys" for 2025

The technology industry is well-positioned for significant growth thanks to the rapid advancements in emerging technologies and the digitization of business operations. Amid this backdrop, fundamentally solid tech stocks Adobe (ADBE), Leidos Holdings (LDOS), and DocuSign (DOCU) could be strong buys for 2025. Continue reading...

3 Tech Stocks Under $20 With Breakout Potential

The tech sector is the core of innovation, from transforming industries to powering economic progress. Amid this backdrop, investors could consider buying sound under $20 tech stocks Vimeo (VMEO), PubMatic (PUBM), and Eventbrite (EB). Keep reading…

How Bad Will 2025 Be for Stocks?

As January goes...so goes the stock market. And right now that saying bodes poorly for the year ahead. Especially for the S&P 500 (SPY). That is why Steve Reitmeister shares 2 different paths the market could take in 2025 and how to get your portfolio on the right side of the action.

Read More Stories

More JPMorgan Chase & Co. (JPM) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All JPM News